Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by AstraZeneca
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00579150
First received: December 19, 2007
Last updated: May 19, 2015
Last verified: May 2015

December 19, 2007
May 19, 2015
January 2009
January 2020   (final data collection date for primary outcome measure)
Primary Outcome [ Time Frame: For each group, primary outcome measure will be assessed among all births, including major birth defects identified during the postnatal period and up to infant age 12 months. ] [ Designated as safety issue: Yes ]
For each group, the primary outcome measure will be percentage of major birth defects—i.e., those that caused significant functional or cosmetic impairment, required surgery, or were life-limiting—among all births, including major birth defects identified during the postnatal period and up to infant age 12 months. For each group, the primary outcome measure will be percentage of major birth defects—i.e., those that caused significant functional or cosmetic impairment, required surgery, or were life-limiting—among all births, including major birth defects identified during the postnatal period and up to infant age 12 months.
Not Provided
Complete list of historical versions of study NCT00579150 on ClinicalTrials.gov Archive Site
Secondary Outcome Measure [ Time Frame: For each group, secondary outcome measures will be assessed among all identified pregnancies. ] [ Designated as safety issue: Yes ]
For each group, the secondary outcome measure is to evaluate the percentage of the following outcomes among pregnancies or births in women with type 2 diabetes: Recognized spontaneous abortion (<20weeks gestation), Stillbirth (death of fetus at >/= weeks gestation, Preterm birth (<37 weeks gestation, infant macrosomia (>4,000 grams), low birth weight infants (<2,50o grams). To examine any potential impact of breastfeeding on infant growth during the first 4 months of life.
Not Provided
Not Provided
Not Provided
 
Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy
Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

This is an observational, prospective cohort study describing pregnancy outcomes in women with pre-existing (prior to pregnancy) type 2 diabetes who have been exposed to any formulation of exenatide during pregnancy. The pregnancy registry will compare the occurrence of the pregnancy outcomes of interest with those collected from a prospective group of women with pre-existing type 2 diabetes who have been exposed to one or more antidiabetic medications other than exenatide during pregnancy. Insulin exposures are acceptable in both groups but must be in addition to one or more other antidiabetic medications in the non-exenatide group.

The primary study objective is to evaluate the percentage of major birth defects (i.e., those that caused significant functional or cosmetic impairment, required surgery, or were life-limiting) following use of exenatide during pregnancy for treatment of type 2 diabetes compared to the percentage of major birth defects following use of one or more antidiabetic medications other than exenatide during pregnancy for treatment of type 2 diabetes.

The secondary objectives of the Exenatide Pregnancy Registry are to evaluate the percentage of other adverse pregnancy outcomes (e.g., spontaneous abortion, stillbirth, preterm birth) and any potential impact of exenatide use during breastfeeding among pregnancies or births in women who used exenatide for pre-existing type 2 diabetes:

This study is being conducted in the United States (US). Enrollment in the Registry is voluntary. The Exenatide Pregnancy Registry is sponsored by AstraZeneca and is managed by INC Research, LLC. The scientific conduct and analysis of the Registry is overseen by a Registry Review Committee (RRC) consisting of experts in maternal and fetal medicine, teratology/genetics, epidemiology, type 2 diabetes in pregnancy and/or pediatrics.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Is pregnant and at least 18 years of age at the time of enrollment

  • Birth Defects
  • Type 2 Diabetes
  • Preterm Birth
Not Provided
  • Exenatide
    Exposure to any form of exenatide during pregnancy for treatment of type 2 diabetes. Patients also taking Insulin may be included, though only as part of a combination treatment.
  • Non-exenatide group
    Exposure to non-insulin antidiabetic medication not including exenatide for treatment of pre-existing type 2 diabetes during pregnancy. Patients also taking Insulin may be included, though only as part of a combination treatment.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
400
January 2020
January 2020   (final data collection date for primary outcome measure)

Inclusion Criteria:

The subjects must meet the following eligibility criteria for participation in the registry:

  • Is pregnant and at least 18 years of age at the time of enrollment
  • Had a diagnosis of type 2 diabetes prior to pregnancy
  • Does not know the pregnancy outcome at the time of enrollment
  • Has no knowledge of any existing structural or chromosomal defects detected on a prenatal test prior to enrollment
  • Had been exposed to an immediate release formulation of exenatide (e.g. BYETTA®) or a non-insulin antidiabetic medication other than exenatide on or after the first day of the last menstrual period (insulin use will be allowed for both groups). OR participant has been exposed to an extended release formulation of exenatide (e.g. BYDUREON®) within 8 weeks of the first day of the last menstrual period
  • Is willing and able to provide informed consent and an authorization for the pregnancy registry to contact the obstetric HCP, diabetes HCP, and the infant's pediatric HCP (and complete contact information for these practitioners, if different, and if available)
  • Is able to understand spoken English or Spanish
Female
18 Years and older
No
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com
United States
 
NCT00579150
D5550C00004, BCA401
Yes
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Vikki Brown, MD INC Research
Study Director: Esther Pascual AstraZeneca
AstraZeneca
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP